(ABT) Abbott Laboratories - Ratings and Ratios
Pharmaceuticals, Diagnostics, Nutrition, Devices, Generic
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 19.3% |
| Value at Risk 5%th | 29.9% |
| Relative Tail Risk | -5.87% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.54 |
| Alpha | 8.98 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.479 |
| Beta | 0.235 |
| Beta Downside | 0.440 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.88% |
| Mean DD | 6.60% |
| Median DD | 5.48% |
Description: ABT Abbott Laboratories September 24, 2025
Abbott Laboratories (NYSE: ABT) operates globally across four core segments-Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices-leveraging a diversified portfolio that spans generic drugs, vaccines, point-of-care diagnostics, infant nutrition, cardiovascular implants, diabetes monitoring, and neuromodulation therapies.
The pharmaceutical arm supplies generics for a wide array of conditions (e.g., pancreatic exocrine insufficiency, dyslipidemia, hypertension, migraine) and specialty anti-infectives such as clarithromycin, while the diagnostics division offers immunoassay, clinical chemistry, hematology, molecular PCR platforms, rapid lateral-flow tests for pathogens (including SARS-CoV-2 and influenza), and cardiometabolic testing kits. The nutrition segment includes pediatric formulas and adult health supplements, and the medical-device business covers rhythm-management, heart-failure, vascular, structural-heart, diabetes-care, and chronic-pain neuromodulation devices.
Recent financial metrics (FY 2023) show revenue of $43.1 billion, a diluted EPS of $2.86, and free cash flow of roughly $6.5 billion, supporting a dividend yield near 1.5 % and a 2024-2025 share-repurchase plan of $5 billion. Abbott’s R&D spend averaged $3.2 billion (≈7.4 % of sales), reflecting its commitment to pipeline renewal in high-growth areas such as molecular diagnostics and cardiovascular devices. These figures are subject to macro-economic volatility, particularly currency fluctuations and US healthcare policy shifts, which could materially affect earnings.
Key sector drivers include an aging U.S. and global population that fuels demand for chronic-disease therapeutics, sustained growth in point-of-care testing accelerated by post-pandemic health-security concerns, and incremental pricing pressure from generic competition. Assuming continued reimbursement stability and no major supply-chain disruptions, Abbott’s diversified exposure positions it to capture a portion of the projected 5-6 % CAGR in global medical-device spend over the next five years.
For a deeper, data-driven valuation framework, the ValueRay platform provides granular scenario analysis that can help quantify Abbott’s upside and downside risks.
ABT Stock Overview
| Market Cap in USD | 224,767m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1978-01-13 |
| Return 12m vs S&P 500 | -0.64% |
| Analyst Rating | 4.11 of 5 |
ABT Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 1.82% |
| Yield on Cost 5y | 2.33% |
| Yield CAGR 5y | 11.18% |
| Payout Consistency | 96.8% |
| Payout Ratio | 47.3% |
ABT Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 9.63% |
| CAGR/Max DD Calmar Ratio | 0.46 |
| CAGR/Mean DD Pain Ratio | 1.46 |
| Current Volume | 6774.2k |
| Average Volume | 5293.9k |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (13.98b TTM) > 0 and > 6% of Revenue (6% = 2.63b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -0.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 23.39% (prev 21.59%; Δ 1.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 9.12b <= Net Income 13.98b (YES >=105%, WARN >=100%) |
| Net Debt (5.43b) to EBITDA (10.93b) ratio: 0.50 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.75b) change vs 12m ago 0.06% (target <= -2.0% for YES) |
| Gross Margin 53.98% (prev 50.98%; Δ 3.01pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.31% (prev 55.43%; Δ -0.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 14.11 (EBITDA TTM 10.93b / Interest Expense TTM 451.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.81
| (A) 0.12 = (Total Current Assets 24.84b - Total Current Liabilities 14.58b) / Total Assets 84.18b |
| (B) 0.58 = Retained Earnings (Balance) 49.10b / Total Assets 84.18b |
| (C) 0.08 = EBIT TTM 6.37b / Avg Total Assets 79.27b |
| (D) 1.49 = Book Value of Equity 49.10b / Total Liabilities 32.92b |
| Total Rating: 4.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.01
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 2.97% = 1.49 |
| 3. FCF Margin 15.78% = 3.94 |
| 4. Debt/Equity 0.30 = 2.46 |
| 5. Debt/Ebitda 0.50 = 2.31 |
| 6. ROIC - WACC (= 1.17)% = 1.46 |
| 7. RoE 28.24% = 2.35 |
| 8. Rev. Trend 86.86% = 6.51 |
| 9. EPS Trend 69.64% = 3.48 |
What is the price of ABT shares?
Over the past week, the price has changed by +2.36%, over one month by +0.38%, over three months by +0.24% and over the past year by +12.87%.
Is ABT a buy, sell or hold?
- Strong Buy: 12
- Buy: 7
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 144.5 | 11.1% |
| Analysts Target Price | 144.5 | 11.1% |
| ValueRay Target Price | 137.6 | 5.8% |
ABT Fundamental Data Overview November 15, 2025
P/E Trailing = 16.2387
P/E Forward = 22.7273
P/S = 5.1266
P/B = 4.3962
P/EG = 4.1675
Beta = 0.719
Revenue TTM = 43.84b USD
EBIT TTM = 6.37b USD
EBITDA TTM = 10.93b USD
Long Term Debt = 11.60b USD (from longTermDebt, last quarter)
Short Term Debt = 1.34b USD (from shortLongTermDebt, last quarter)
Debt = 15.28b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 5.43b USD (from netDebt column, last quarter)
Enterprise Value = 232.53b USD (224.77b + Debt 15.28b - CCE 7.51b)
Interest Coverage Ratio = 14.11 (Ebit TTM 6.37b / Interest Expense TTM 451.0m)
FCF Yield = 2.97% (FCF TTM 6.92b / Enterprise Value 232.53b)
FCF Margin = 15.78% (FCF TTM 6.92b / Revenue TTM 43.84b)
Net Margin = 31.88% (Net Income TTM 13.98b / Revenue TTM 43.84b)
Gross Margin = 53.98% ((Revenue TTM 43.84b - Cost of Revenue TTM 20.18b) / Revenue TTM)
Gross Margin QoQ = 55.75% (prev 56.44%)
Tobins Q-Ratio = 2.76 (Enterprise Value 232.53b / Total Assets 84.18b)
Interest Expense / Debt = 0.29% (Interest Expense 44.0m / Debt 15.28b)
Taxrate = 24.59% (536.0m / 2.18b)
NOPAT = 4.80b (EBIT 6.37b * (1 - 24.59%))
Current Ratio = 1.70 (Total Current Assets 24.84b / Total Current Liabilities 14.58b)
Debt / Equity = 0.30 (Debt 15.28b / totalStockholderEquity, last quarter 50.95b)
Debt / EBITDA = 0.50 (Net Debt 5.43b / EBITDA 10.93b)
Debt / FCF = 0.79 (Net Debt 5.43b / FCF TTM 6.92b)
Total Stockholder Equity = 49.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.60% (Net Income 13.98b / Total Assets 84.18b)
RoE = 28.24% (Net Income TTM 13.98b / Total Stockholder Equity 49.50b)
RoCE = 10.42% (EBIT 6.37b / Capital Employed (Equity 49.50b + L.T.Debt 11.60b))
RoIC = 7.63% (NOPAT 4.80b / Invested Capital 62.93b)
WACC = 6.46% (E(224.77b)/V(240.04b) * Re(6.88%) + D(15.28b)/V(240.04b) * Rd(0.29%) * (1-Tc(0.25)))
Discount Rate = 6.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.03%
[DCF Debug] Terminal Value 77.94% ; FCFE base≈6.74b ; Y1≈6.59b ; Y5≈6.67b
Fair Price DCF = 68.12 (DCF Value 118.45b / Shares Outstanding 1.74b; 5y FCF grow -3.37% → 3.0% )
EPS Correlation: 69.64 | EPS CAGR: 8.83% | SUE: 0.0 | # QB: 0
Revenue Correlation: 86.86 | Revenue CAGR: 4.43% | SUE: -0.19 | # QB: 0
Additional Sources for ABT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle